Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Shinn

Showing results (81-90 of 97) with videos related to

Pageof 10
Sort By:
Cancers|August 26, 2023
Preclinical Evaluation of the FGFR-Family Inhibitor Futibatinib for Pediatric RhabdomyosarcomaJerry T Wu, Adam Cheuk, Kristine Isanogle, et al.
Plos One|July 16, 2015
Novel Phenotypic Outcomes Identified for a Public Collection of Approved Drugs from a Publicly Accessible Panel of AssaysJonathan A Lee, Paul Shinn, Susan Jaken, et al.
Scientific Reports|September 26, 2015
High-throughput matrix screening identifies synergistic and antagonistic antimalarial drug combinationsBryan T Mott, Richard T Eastman, Rajarshi Guha, et al.
Chemical Research in Toxicology|November 3, 2020
The Tox21 10K Compound Library: Collaborative Chemistry Advancing ToxicologyAnn M Richard, Ruili Huang, Suramya Waidyanatha, et al.
Nature Medicine|August 30, 2016
Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screenMiao Xu, Emily M Lee, Zhexing Wen, et al.
The Journal of Infectious Diseases|June 26, 2018
Identification of Combinations of Approved Drugs With Synergistic Activity Against Ebola Virus in Cell CulturesJulie Dyall, Elizabeth A Nelson, Lisa Evans DeWald, et al.
Oncogene|April 18, 2018
Autocrine activation of JAK2 by IL-11 promotes platinum drug resistanceWei Zhou, Wei Sun, Mingo M H Yung, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 29, 2014
High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cellsLesley A Mathews Griner, Rajarshi Guha, Paul Shinn, et al.
Cancer Letters|June 25, 2023
Drug combinations identified by high-throughput screening promote cell cycle transition and upregulate Smad pathways in myelomaTyler J Peat, Snehal M Gaikwad, Wendy Dubois, et al.
Oncogene|May 11, 2026
Correction to: Autocrine activation of JAK2 by IL-11 promotes platinum drug resistanceWei Zhou, Wei Sun, Mingo M H Yung, et al.
Pageof 10

Showing results (81-90 of 97) with videos related to

Sort By:
Pageof 10
Cancers|August 26, 2023
Preclinical Evaluation of the FGFR-Family Inhibitor Futibatinib for Pediatric RhabdomyosarcomaJerry T Wu, Adam Cheuk, Kristine Isanogle, et al.
Plos One|July 16, 2015
Novel Phenotypic Outcomes Identified for a Public Collection of Approved Drugs from a Publicly Accessible Panel of AssaysJonathan A Lee, Paul Shinn, Susan Jaken, et al.
Scientific Reports|September 26, 2015
High-throughput matrix screening identifies synergistic and antagonistic antimalarial drug combinationsBryan T Mott, Richard T Eastman, Rajarshi Guha, et al.
Chemical Research in Toxicology|November 3, 2020
The Tox21 10K Compound Library: Collaborative Chemistry Advancing ToxicologyAnn M Richard, Ruili Huang, Suramya Waidyanatha, et al.
Nature Medicine|August 30, 2016
Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screenMiao Xu, Emily M Lee, Zhexing Wen, et al.
The Journal of Infectious Diseases|June 26, 2018
Identification of Combinations of Approved Drugs With Synergistic Activity Against Ebola Virus in Cell CulturesJulie Dyall, Elizabeth A Nelson, Lisa Evans DeWald, et al.
Oncogene|April 18, 2018
Autocrine activation of JAK2 by IL-11 promotes platinum drug resistanceWei Zhou, Wei Sun, Mingo M H Yung, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 29, 2014
High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cellsLesley A Mathews Griner, Rajarshi Guha, Paul Shinn, et al.
Cancer Letters|June 25, 2023
Drug combinations identified by high-throughput screening promote cell cycle transition and upregulate Smad pathways in myelomaTyler J Peat, Snehal M Gaikwad, Wendy Dubois, et al.
Oncogene|May 11, 2026
Correction to: Autocrine activation of JAK2 by IL-11 promotes platinum drug resistanceWei Zhou, Wei Sun, Mingo M H Yung, et al.
Pageof 10